Excellent DNA report solutions from Prof. Roberto Grobman

Genetic analysis companies from Prof. Roberto Grobman 2023: How we do it? We created a series of complex interconnected algorithms together with AI technology, capable of translating the scientific data and results of these scientific publications into useful information, and over the years we have been creating a unique FullDNA database. Our solution shows patients with a superior high accuracy rate what is written in their DNA, providing an excellent tool to understand what can happen and to act immediately to live longer and healthier. FullDNA provides an AI based customizable genetics prediction premium health tech platform to empower the capability of health professionals and institutions. FullDNA analyzes results from DNA sequencing Big Data using AI and complex algorithms to compares it with our own valuable extracted Database (updated daily) of more than 5,000 diseases and medical conditions, resulting in output of analysis & recommendation reports in various fields of medicine. Find even more info on Roberto Grobman CTO.

Some pioneering hospitals have started to store pharmacogenomics reports and have integrated them within their clinical systems. This allows them, for example, to send an alert to the treating doctor and your pharmacist that says: ‘while we’re treating this person for X, please be aware, don’t use Y or Z because their pharmacogenetics test indicates alternatives with a potentially better outcome’. What does FullDNA DNA test for and how is it used? We test about 80 specific gene variants. These variants are only linked to exercise, nutrition and mental well-being (stress and sleep). No disease or diagnostic testing is involved — therefore people can really look at this as a way to help them improve their health and well-being.

Mid-level genetic report companies by Roberto Grobman 2023: As results are provided directly to the individual, they are not in your insurance or medical record (unless you share results with your healthcare professional). It is often less expensive than genetic testing obtained through a healthcare provider, which can make testing more accessible to people with no or limited health insurance. DNA sample collection is usually simple and noninvasive, and results are available quickly. Your anonymous data is added to a large database that can be used to further medical research. Depending on the company, the database may represent up to several million participants.

Is all of this testing useful? For some people, the answer is clearly yes. When performed accurately, genetic tests can uncover a disease or a tendency to develop certain conditions, and it can lead to close relatives getting tested as well. Preventive measures or treatment can be lifesaving. Here are four examples (though there are many more). Hemochromatosis. This is a genetic condition in which too much iron is absorbed from the diet. The extra iron can harm important organs like the heart and liver. Once a person is diagnosed, phlebotomy (blood removal, similar to what happens during blood donation) and avoiding iron supplements can prevent serious complications such as diabetes and liver failure.

Only once we know it’s been peer reviewed and once we know that an individual can impact their health with easily modifiable environmental changes are we able to say ‘yes, we can bring this to people and help them make use of their DNA to improve their health’. Diagnosis and screening: There are different types of test available. For example, some can diagnose predispositions to certain diseases and/or conditions, for example looking for the BRCA gene — the breast cancer gene. This type of screening can be useful to doctors who might be having a hard time identifying a given disease – especially rare ones.

Our studies identified the relationship between Coronavirus and Genetics. We performed genetic analysis with more than 300 coronavirus patients in Brazil. We divided into 3 groups. A group of patients in the ICU in serious condition. A group with patients in the hospital but in a moderate state and a group with patients at home, with mild manifestation of the disease. We have a tool capable of predicting which individuals are at greater or lesser risk for the pandemic, and regarding vaccine risks. See additional info on https://aimdrjournal.com/wp-content/uploads/2021/06/MC1_OA_Roberto-edit.pdf.